Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.06
TMO's Cash to Debt is ranked lower than
96% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. TMO: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
TMO' s 10-Year Cash to Debt Range
Min: 0.04  Med: 0.41 Max: 2.34
Current: 0.06
0.04
2.34
Equity to Asset 0.50
TMO's Equity to Asset is ranked lower than
68% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TMO: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
TMO' s 10-Year Equity to Asset Range
Min: 0.31  Med: 0.56 Max: 0.75
Current: 0.5
0.31
0.75
Interest Coverage 5.22
TMO's Interest Coverage is ranked lower than
87% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. TMO: 5.22 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s 10-Year Interest Coverage Range
Min: 3.21  Med: 7.14 Max: 21.63
Current: 5.22
3.21
21.63
F-Score: 7
Z-Score: 2.41
M-Score: -2.59
WACC vs ROIC
7.69%
6.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.02
TMO's Operating margin (%) is ranked higher than
85% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. TMO: 14.02 )
Ranked among companies with meaningful Operating margin (%) only.
TMO' s 10-Year Operating margin (%) Range
Min: 1.56  Med: 10.58 Max: 14.82
Current: 14.02
1.56
14.82
Net-margin (%) 11.69
TMO's Net-margin (%) is ranked higher than
84% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. TMO: 11.69 )
Ranked among companies with meaningful Net-margin (%) only.
TMO' s 10-Year Net-margin (%) Range
Min: -7.07  Med: 9.10 Max: 16.75
Current: 11.69
-7.07
16.75
ROE (%) 9.62
TMO's ROE (%) is ranked higher than
69% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. TMO: 9.62 )
Ranked among companies with meaningful ROE (%) only.
TMO' s 10-Year ROE (%) Range
Min: -8.18  Med: 7.88 Max: 15.73
Current: 9.62
-8.18
15.73
ROA (%) 4.61
TMO's ROA (%) is ranked higher than
71% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. TMO: 4.61 )
Ranked among companies with meaningful ROA (%) only.
TMO' s 10-Year ROA (%) Range
Min: -3.29  Med: 4.34 Max: 10.39
Current: 4.61
-3.29
10.39
ROC (Joel Greenblatt) (%) 50.76
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. TMO: 50.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TMO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.07  Med: 40.02 Max: 62.95
Current: 50.76
4.07
62.95
Revenue Growth (3Y)(%) 11.80
TMO's Revenue Growth (3Y)(%) is ranked higher than
75% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. TMO: 11.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TMO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.9  Med: 7.50 Max: 18.7
Current: 11.8
-12.9
18.7
EBITDA Growth (3Y)(%) 23.40
TMO's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TMO: 23.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TMO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30  Med: 13.60 Max: 40.8
Current: 23.4
-30
40.8
EPS Growth (3Y)(%) 21.00
TMO's EPS Growth (3Y)(%) is ranked higher than
82% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. TMO: 21.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TMO' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.3  Med: 11.50 Max: 74.6
Current: 21
-41.3
74.6
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

TMO Guru Trades in Q3 2014

Vanguard Health Care Fund 1,494,300 sh (New)
Joel Greenblatt 3,314 sh (New)
Jim Simons 37,844 sh (New)
Caxton Associates 45,000 sh (New)
Eric Mindich 1,119,000 sh (+159.03%)
Signature Select Canadian Fund 122,600 sh (+38.06%)
Bill Frels 2,381 sh (+33.39%)
PRIMECAP Management 4,308,150 sh (+8.73%)
Larry Robbins 11,375,667 sh (+3.96%)
First Pacific Advisors 3,549,700 sh (+0.81%)
John Rogers 540,702 sh (+0.70%)
First Eagle Investment 200 sh (unchged)
Steven Romick 3,315,000 sh (unchged)
Ruane Cunniff 3,101 sh (unchged)
John Griffin 2,715,000 sh (unchged)
Pioneer Investments 1,985,531 sh (unchged)
John Paulson Sold Out
Scott Black 79,249 sh (-0.51%)
David Dreman 16,213 sh (-1.26%)
Andreas Halvorsen 7,976,502 sh (-3.56%)
Leon Cooperman 864,000 sh (-3.87%)
Dodge & Cox 57,082 sh (-29.53%)
Steven Cohen 79,800 sh (-46.23%)
Paul Tudor Jones 3,200 sh (-49.92%)
» More
Q4 2014

TMO Guru Trades in Q4 2014

Ray Dalio 11,899 sh (New)
Mario Gabelli 13,000 sh (New)
Jim Simons 206,644 sh (+446.04%)
Steven Cohen 239,700 sh (+200.38%)
Paul Tudor Jones 4,763 sh (+48.84%)
Vanguard Health Care Fund 2,179,000 sh (+45.82%)
Eric Mindich 1,563,000 sh (+39.68%)
John Rogers 580,501 sh (+7.36%)
PRIMECAP Management 4,487,090 sh (+4.15%)
Bill Frels 2,446 sh (+2.73%)
Steven Romick 3,381,300 sh (+2.00%)
First Pacific Advisors 3,617,400 sh (+1.91%)
Larry Robbins 11,387,265 sh (+0.10%)
First Eagle Investment 200 sh (unchged)
Joel Greenblatt Sold Out
Leon Cooperman Sold Out
Caxton Associates Sold Out
Pioneer Investments 1,965,136 sh (-1.03%)
David Dreman 15,984 sh (-1.41%)
Dodge & Cox 56,202 sh (-1.54%)
Scott Black 74,862 sh (-5.54%)
Ruane Cunniff 2,873 sh (-7.35%)
John Griffin 2,115,000 sh (-22.10%)
Andreas Halvorsen 5,786,510 sh (-27.46%)
» More
Q1 2015

TMO Guru Trades in Q1 2015

Caxton Associates 30,000 sh (New)
Mario Gabelli 23,315 sh (+79.35%)
Paul Tudor Jones 8,461 sh (+77.64%)
Jim Simons 250,144 sh (+21.05%)
PRIMECAP Management 5,168,990 sh (+15.20%)
Pioneer Investments 2,138,986 sh (+8.85%)
John Rogers 586,411 sh (+1.02%)
Caxton Associates 40,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Eric Mindich 1,563,000 sh (unchged)
Vanguard Health Care Fund 2,179,000 sh (unchged)
Ruane Cunniff 2,873 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Scott Black 74,759 sh (-0.14%)
Signature Select Canadian Fund 121,000 sh (-1.31%)
Bill Frels 2,381 sh (-2.66%)
Dodge & Cox 53,802 sh (-4.27%)
David Dreman 15,282 sh (-4.39%)
First Pacific Advisors 3,410,800 sh (-5.71%)
Steven Romick 3,180,000 sh (-5.95%)
John Griffin 1,950,000 sh (-7.80%)
Andreas Halvorsen 3,531,837 sh (-38.96%)
Larry Robbins 6,910,771 sh (-39.31%)
» More
Q2 2015

TMO Guru Trades in Q2 2015

Ray Dalio 43,723 sh (New)
Steven Cohen 33,300 sh (New)
Larry Robbins 9,259,710 sh (+33.99%)
Vanguard Health Care Fund 2,679,000 sh (+22.95%)
Mario Gabelli 26,450 sh (+13.45%)
PRIMECAP Management 5,520,640 sh (+6.80%)
Pioneer Investments 2,171,128 sh (+1.50%)
First Pacific Advisors 3,448,400 sh (+1.10%)
First Eagle Investment 200 sh (unchged)
Ruane Cunniff 2,873 sh (unchged)
Steven Romick 3,180,000 sh (unchged)
Dodge & Cox 53,802 sh (unchged)
Caxton Associates Sold Out
Eric Mindich Sold Out
Paul Tudor Jones Sold Out
John Rogers 585,261 sh (-0.20%)
Bill Frels 2,335 sh (-1.93%)
David Dreman 14,632 sh (-4.25%)
Scott Black 60,041 sh (-19.69%)
Jim Simons 188,344 sh (-24.71%)
John Griffin 1,190,000 sh (-38.97%)
Andreas Halvorsen 207,527 sh (-94.12%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Thermo Fisher Scientific Inc

John Rogers Comments on Thermo Fisher Scientific Inc. - May 07, 2014

In addition, scientific research specialist Thermo Fisher Scientific Inc. (TMO) returned +8.12% after a very solid earnings report. Its revenue was $3.5 billion, up 6% over the previous period, and its earnings per share was $1.43, significantly above the $1.37 cons ensus estimate. Its forecast for 2014 was even more positive : full-year revenue guidance was in the $16 billion-plus ra nge, smashing the $13 billion consensus estimate, and the low end of its EPS guidance was more than $0.40 higher than Wall Street's best guess. Our strategy with Thermo Fisher has been to look beyond the gloom and doom that has cast a dark cloud over the whole sector to see the potential for a bright future.



From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund first quarter 2014 letter.

Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 25.90
TMO's P/E(ttm) is ranked higher than
60% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. TMO: 25.90 )
Ranked among companies with meaningful P/E(ttm) only.
TMO' s 10-Year P/E(ttm) Range
Min: 11.11  Med: 23.37 Max: 55.16
Current: 25.9
11.11
55.16
Forward P/E 15.24
TMO's Forward P/E is ranked higher than
73% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. TMO: 15.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.90
TMO's PE(NRI) is ranked higher than
60% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. TMO: 25.90 )
Ranked among companies with meaningful PE(NRI) only.
TMO' s 10-Year PE(NRI) Range
Min: 13.48  Med: 24.28 Max: 54.55
Current: 25.9
13.48
54.55
P/B 2.44
TMO's P/B is ranked higher than
63% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. TMO: 2.44 )
Ranked among companies with meaningful P/B only.
TMO' s 10-Year P/B Range
Min: 0.83  Med: 1.59 Max: 2.73
Current: 2.44
0.83
2.73
P/S 3.02
TMO's P/S is ranked lower than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. TMO: 3.02 )
Ranked among companies with meaningful P/S only.
TMO' s 10-Year P/S Range
Min: 1.24  Med: 2.19 Max: 3.48
Current: 3.02
1.24
3.48
PFCF 25.05
TMO's PFCF is ranked lower than
51% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. TMO: 25.05 )
Ranked among companies with meaningful PFCF only.
TMO' s 10-Year PFCF Range
Min: 10.22  Med: 19.87 Max: 32.28
Current: 25.05
10.22
32.28
POCF 20.61
TMO's POCF is ranked lower than
51% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. TMO: 20.61 )
Ranked among companies with meaningful POCF only.
TMO' s 10-Year POCF Range
Min: 8.72  Med: 16.91 Max: 26.55
Current: 20.61
8.72
26.55
EV-to-EBIT 26.40
TMO's EV-to-EBIT is ranked lower than
63% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. TMO: 26.40 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s 10-Year EV-to-EBIT Range
Min: 11.2  Med: 22.10 Max: 73.5
Current: 26.4
11.2
73.5
PEG 1.42
TMO's PEG is ranked higher than
76% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. TMO: 1.42 )
Ranked among companies with meaningful PEG only.
TMO' s 10-Year PEG Range
Min: 0.56  Med: 1.63 Max: 11.39
Current: 1.42
0.56
11.39
Shiller P/E 35.12
TMO's Shiller P/E is ranked lower than
60% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. TMO: 35.12 )
Ranked among companies with meaningful Shiller P/E only.
TMO' s 10-Year Shiller P/E Range
Min: 16.89  Med: 30.95 Max: 56.74
Current: 35.12
16.89
56.74
Current Ratio 1.02
TMO's Current Ratio is ranked lower than
89% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. TMO: 1.02 )
Ranked among companies with meaningful Current Ratio only.
TMO' s 10-Year Current Ratio Range
Min: 0.9  Med: 2.37 Max: 3.83
Current: 1.02
0.9
3.83
Quick Ratio 0.70
TMO's Quick Ratio is ranked lower than
89% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TMO: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s 10-Year Quick Ratio Range
Min: 0.61  Med: 1.71 Max: 3.4
Current: 0.7
0.61
3.4
Days Inventory 77.06
TMO's Days Inventory is ranked higher than
50% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. TMO: 77.06 )
Ranked among companies with meaningful Days Inventory only.
TMO' s 10-Year Days Inventory Range
Min: 65.13  Med: 88.88 Max: 183.33
Current: 77.06
65.13
183.33
Days Sales Outstanding 56.98
TMO's Days Sales Outstanding is ranked higher than
58% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. TMO: 56.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s 10-Year Days Sales Outstanding Range
Min: 50.89  Med: 74.84 Max: 159.82
Current: 56.98
50.89
159.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.47
TMO's Dividend Yield is ranked lower than
90% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. TMO: 0.47 )
Ranked among companies with meaningful Dividend Yield only.
TMO' s 10-Year Dividend Yield Range
Min: 0.22  Med: 0.51 Max: 0.86
Current: 0.47
0.22
0.86
Dividend Payout 0.12
TMO's Dividend Payout is ranked higher than
94% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. TMO: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
TMO' s 10-Year Dividend Payout Range
Min: 0.1  Med: 0.16 Max: 0.22
Current: 0.12
0.1
0.22
Yield on cost (5-Year) 0.47
TMO's Yield on cost (5-Year) is ranked lower than
93% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. TMO: 0.47 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TMO' s 10-Year Yield on cost (5-Year) Range
Min: 0.22  Med: 0.51 Max: 0.86
Current: 0.47
0.22
0.86
Share Buyback Rate -1.50
TMO's Share Buyback Rate is ranked higher than
62% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.70 vs. TMO: -1.50 )
Ranked among companies with meaningful Share Buyback Rate only.
TMO' s 10-Year Share Buyback Rate Range
Min: 4.6  Med: -1.30 Max: -38.3
Current: -1.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.25
TMO's Price/Projected FCF is ranked higher than
77% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. TMO: 1.25 )
Ranked among companies with meaningful Price/Projected FCF only.
TMO' s 10-Year Price/Projected FCF Range
Min: 0.6  Med: 1.28 Max: 43.45
Current: 1.25
0.6
43.45
Price/DCF (Earnings Based) 1.23
TMO's Price/DCF (Earnings Based) is ranked higher than
87% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. TMO: 1.23 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.38
TMO's Price/Median PS Value is ranked lower than
77% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. TMO: 1.38 )
Ranked among companies with meaningful Price/Median PS Value only.
TMO' s 10-Year Price/Median PS Value Range
Min: 0.38  Med: 0.92 Max: 1.49
Current: 1.38
0.38
1.49
Price/Peter Lynch Fair Value 1.36
TMO's Price/Peter Lynch Fair Value is ranked higher than
73% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.96 vs. TMO: 1.36 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TMO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.59  Med: 1.63 Max: 14.2
Current: 1.36
0.59
14.2
Earnings Yield (Greenblatt) (%) 3.80
TMO's Earnings Yield (Greenblatt) (%) is ranked higher than
68% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. TMO: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TMO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.4  Med: 4.50 Max: 8.9
Current: 3.8
1.4
8.9
Forward Rate of Return (Yacktman) (%) 22.55
TMO's Forward Rate of Return (Yacktman) (%) is ranked higher than
82% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. TMO: 22.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TMO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -19.2  Med: 20.50 Max: 34.8
Current: 22.55
-19.2
34.8

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 16,816 17,568 18,370
EPS($) 7.41 8.30 9.32
EPS without NRI($) 7.41 8.30 9.32

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, COO, ISRG » details
Traded in other countries:TMO.Mexico, TN8.Germany,
Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves more than 400,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Moody Lynn & Lieberson Top Buys in Second Quarter Aug 27 2015 
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Steven Romick Sells Stakes in 4 Companies Jul 01 2015 
Andreas Halvorsen Sells More Than Half of His Stake in Valeant Jun 18 2015 
Virtusa and magicJack VocalTec Profit Above Projections; Pall Buyout Attraction May 12 2015 
Compass Capital Management's Top 3 Picks During Q1 May 11 2015 
Steven Romick's FPA Crescent Fund First Quarter 2015 Commentary May 06 2015 
Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
The Gurus to Follow Based on Sector — Part 2 Dec 09 2014 
Glenview's Larry Robbins Adds to Stake in Watchmaker Fossil Sep 15 2014 

More From Other Websites
New Line of Radiation Area Monitors Eliminates Operational Requirements for On-site Nuclear Power... Aug 28 2015
Thermo Fisher: Life Technologies Synergy on Track Post Q2 Aug 24 2015
Want to work from home? Check out these jobs Aug 22 2015
Billionaire Larry Robbins Has Healthy Stakes In Health Stocks Aug 20 2015
THERMO FISHER SCIENTIFIC INC. Financials Aug 06 2015
10-Q for Thermo Fisher Scientific, Inc. Aug 03 2015
THERMO FISHER SCIENTIFIC INC. Files SEC form 10-Q, Quarterly Report Jul 31 2015
New Modular Rheometers Offer Flexibility and Reduce User Error With Connect Assist Technology Jul 31 2015
Thermo Fisher Scientific, Inc. Earnings Analysis: By the Numbers Jul 29 2015
5 More Rocket Stocks to Buy for Earnings Season Gains -- Including One Jim Cramer Owns Jul 27 2015
Thermo Fisher Scientific Unveils New Solutions to Advance the Use of Clinical Testing and Improve... Jul 27 2015
Thermo Fisher Scientific Unveils New Solutions to Advance the Use of Clinical Testing and Improve... Jul 27 2015
General Electric Co. Earnings Analysis: By the Numbers Jul 24 2015
Company News for July 23, 2015 - Corporate Summary Jul 23 2015
Thermo Fisher Scientific (TMO) Earnings Report: Q2 2015 Conference Call Transcript Jul 22 2015
Edited Transcript of TMO earnings conference call or presentation 22-Jul-15 12:30pm GMT Jul 22 2015
Thermo Fisher to buy 480-employee chemical maker based in Haverhill Jul 22 2015
Thermo Fisher Tops Q2 Earnings and Revenues, Guides Up - Analyst Blog Jul 22 2015
Thermo Fisher (TMO) Beats Q2 Earnings, Revenue Estimates - Tale of the Tape Jul 22 2015
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK